Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial.
Babak SayadReza KhodarahmiFarid NajafiRonak MiladiZeinab Mohseni AfsharFeizollah MansouriZohreh RahimiMaria ShirvaniMehdi SalimiSiavash VaziriAlireza JanbakhshFatemeh Khosravi ShadmaniArezoo BozorgomidMohammad Hossein ZamanianMandana AfsharianPublished in: The Journal of antimicrobial chemotherapy (2021)
Although treatment with SOF/VEL was safe, adding SOF/VEL to the standard of care did not improve the clinical status or reduce mortality in patients with moderate to severe COVID-19. However, larger randomized clinical trials including more parameters are needed for accurate estimation of the efficacy of SOF/VEL.
Keyphrases
- coronavirus disease
- randomized controlled trial
- sars cov
- healthcare
- palliative care
- quality improvement
- hepatitis c virus
- affordable care act
- study protocol
- pain management
- high resolution
- cardiovascular events
- risk factors
- high intensity
- type diabetes
- systematic review
- mass spectrometry
- cardiovascular disease
- health insurance
- double blind